A Phase 2 interventional study of OPC-41061 7.5mg and OPC-41061 placebo in Cirrhosis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 7 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-03-14.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate the dose response for changes from baseline in body weight as a primary endpoint and to investigate improvement in ascites, abdominal circumference, lower-limb edema, and pleural effusion as secondary endpoints in seven-day repeated oral administration of OPC-41061 at 7.5, 15, and 30 mg/day or placebo in cirrhosis patients with ascites despite taking conventional diuretics.
1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.
This study's enrollment of 104 is above the median of 63 across 841 interventional studies indexed under Fibrosis.
Browse Fibrosis studies →Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Compared within Fibrosis, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with ascites despite taking either of the following combinations of loop diuretics and an anti-aldosterone agent (spironolactone) for at least 7 days prior to start of the study drug administration.
Combination 1: Loop diuretics at indicated below in combination with an anti-aldosterone agent at a daily dose of 25 mg or more
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OPC-41061 placebo
Drug: OPC-41061 7.5mg
Drug: OPC-41061 15mg
Drug: OPC-41601 30mg
7.5mg, 1 tablet a day
placebo, 1 tablet a day
15mg, 1 tablet a day
30mg, 1 tablet a day
Body Weight (Amount of Change)
Changes in body wight from baseline at the final timepoint (LOCF). A linear regression model using changes in body weight from baseline at the final timepoint as the criterion variable and dose as the explanatory variable was fitted to the dataset.
Time frame: Baseline, Day 7 or at the discontied of treatment
Abdominal Circumference
Change in abdominal circumference from baseline (LOCF)
Time frame: Baseline, Day 7 or at the discontied of treatment
| Milestone | Placebo | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg |
|---|---|---|---|---|
| Started | 27 | 26 | 25 | 26 |
| Completed | 23 | 20 | 24 | 21 |
| Not completed | 4 | 6 | 1 | 5 |
| Withdrew: Adverse event | 1 | 1 | 1 | 3 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 2 |
| Withdrew: Resolution of all hepatic edema findings | 1 | 1 | 0 | 0 |
Changes in body wight from baseline at the final timepoint (LOCF). A linear regression model using changes in body weight from baseline at the final timepoint as the criterion variable and dose as the explanatory variable was fitted to the dataset.
| Kg | Placebo | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg |
|---|---|---|---|---|
| Body Weight (Amount of Change) | -0.68 ± 2.50 | -2.31 ± 2.35 | -1.88 ± 2.45 | -1.67 ± 1.46 |
Change in abdominal circumference from baseline (LOCF)
| cm | Placebo | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg |
|---|---|---|---|---|
| Abdominal Circumference | -1.39 ± 3.16 | -2.98 ± 3.22 | -2.42 ± 3.96 | -2.62 ± 2.83 |
Collected over 7 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 5/26 (19.2%) | 18/26 (69.2%) |
| OPC-41061 7.5 mg | — | 0/25 (0%) | 20/25 (80%) |
| OPC-41061 15 mg | — | 1/25 (4%) | 19/25 (76%) |
| OPC-41061 30 mg | — | 3/25 (12%) | 24/25 (96%) |
| Event | Placebo | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg |
|---|---|---|---|---|
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/26 | 0/25 | 0/25 | 1/25 |
| Hepatic FailureHepatobiliary disorders | 1/26 | 0/25 | 0/25 | 1/25 |
| Hepatic EncephalopathyNervous system disorders | 0/26 | 0/25 | 0/25 | 1/25 |
| Renal ImpairmentRenal and urinary disorders | 0/26 | 0/25 | 1/25 | 0/25 |
| Shock HaemorrhagicVascular disorders | 0/26 | 0/25 | 1/25 | 0/25 |
| AnaemiaBlood and lymphatic system disorders | 1/26 | 0/25 | 0/25 | 0/25 |
| Abdominal DistensionGastrointestinal disorders | 1/26 | 0/25 | 0/25 | 0/25 |
| Chronic HepatitisHepatobiliary disorders | 1/26 | 0/25 | 0/25 | 0/25 |
| Hepatorenal SyndromeHepatobiliary disorders | 1/26 | 0/25 | 0/25 | 0/25 |
| Hepatitis BInfections and infestations | 1/26 | 0/25 | 0/25 | 0/25 |
| Event | Placebo | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg |
|---|---|---|---|---|
| ThirstGeneral disorders | 1/26 | 6/25 | 14/25 | 15/25 |
| PollakiuriaRenal and urinary disorders | 0/26 | 8/25 | 5/25 | 12/25 |
| Blood Alkaline Phosphatase IncreasedInvestigations | 1/26 | 6/25 | 3/25 | 2/25 |
| InsomniaPsychiatric disorders | 1/26 | 1/25 | 6/25 | 6/25 |
| ConstipationGastrointestinal disorders | 2/26 | 1/25 | 5/25 | 1/25 |
| DiarrhoeaGastrointestinal disorders | 2/26 | 5/25 | 2/25 | 0/25 |
| Blood Uric Acid IncreasedInvestigations | 1/26 | 3/25 | 4/25 | 5/25 |
| Blood Bilirubin IncreasedInvestigations | 5/26 | 1/25 | 1/25 | 3/25 |
| Blood Osmolarity IncreasedInvestigations | 1/26 | 0/25 | 0/25 | 4/25 |
| Blood Urea IncreasedInvestigations | 4/26 | 4/25 | 4/25 | 3/25 |
2 subjects (1 of placebo and 1 of OPC-41061 30 mg) were excluded by GCP deviation. 1 subject (OPC-41061 7.5 mg) was excluded by receiving a dose 7 times higher than specified daily dose.
| Age, Continuous(years) | Placebo | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg | Total |
|---|---|---|---|---|---|
| Mean | 63.5 ± 10.1 | 64.5 ± 9.4 | 64.8 ± 9.7 | 62.8 ± 10.4 | 63.9 ± 9.8 |
| Age, Categorical(Participants) | Placebo | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 11 | 11 | 13 | 48 |
| >=65 years | 13 | 14 | 14 | 12 | 53 |
| Sex: Female, Male(Participants) | Placebo | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg | Total |
|---|---|---|---|---|---|
| Female | 9 | 7 | 4 | 10 | 30 |
| Male | 17 | 18 | 21 | 15 | 71 |
| Region of Enrollment(participants) | Placebo | OPC-41061 7.5 mg | OPC-41061 15 mg | OPC-41061 30 mg | Total |
|---|---|---|---|---|---|
| Japan | 26 | 25 | 25 | 25 | 101 |
The record gives a start of Jun 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 5 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Co., Ltd. →